Efficacy and safety of tacrolimus ointment 0.03% treatment in a 1-month-old "red baby": A case report
Several trials have indicated that topical tacrolimus is safe and effective for several immunologic-based skin disorders. We report a child <2 months old, who was admitted to our pediatric department because of generalized erythroderma. We started tacrolimus ointment 0.03% therapy by applying the ointment to the skin once daily, on a limited surface of 10 cm2, changing the skin areas only after the disappearance of inflammation. After only one application we observed a marked improvement of the treated area and after another application the localized erythroderma disappeared. We changed the site of application and continued this treatment regime for 4 weeks. After 2 weeks we reduced treatment application once every other day and after an additional 2 weeks we discontinued therapy because of complete resolution of erythroderma. No adverse clinical effect was recorded and tolerance to the treatment was good. We conclude that 0.03% tacrolimus ointment is efficacious and safe even in an infant <2 months of age.
Document Type: Research Article
Publication date: 01 November 2006
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service. - Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Commercial level: Permission to use content
- www.JFoodAllergy.com
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content